Amino acid residues in the transmembrane domains of the CB 1 receptor are important for ligand recognition and signal transduction. We used site-directed mutagenesis to identify the role of two novel and adjacent residues in the TMH II domain, Ile2.62 and Asp2.63. We double mutant suggests that although these residues are not obligatory for agonist recognition, they play a synergistic and crucial role in modulating signal transduction.
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Introduction
Cannabinoids act on cannabinoid receptors to elicit their central nervous system effects as well as peripheral effects. The cannabinoid receptors belong to the Class A rhodopsin-like superfamily of G-protein coupled receptors (GPCRs) (Howlett et al., 2002) . So far, two cannabinoid receptors, CB 1 and CB 2 , have been isolated by molecular cloning (Matsuda et al., 1990; Munro et al., 1993) . Recently there has been some evidence that GPR55 may be a cannabinoid receptor, and other additional non-CB 1 /CB 2 receptors may exist (Johns et al., 2007; Ryberg et al., 2007) . Mutational and computational studies indicate the existence of multiple ligand recognition sites at the CB 1 receptor for structurally diverse cannabinoid ligands (Song and Bonner, 1996; McAllister et al., 2003; Fay et al., 2005; D'Antona et al., 2006b ). These binding sites are contributed predominantly by distinct noncontiguous regions of the hydrophobic transmembrane helixes (TMHs).
Binding of an agonist to the plasma membrane bound receptor triggers its association with G-proteins and consequently a cascade of intracellular signaling events are initiated.
Despite our accumulating knowledge of the cannabinoid receptor, the protein structures that serve as a link between association of a ligand and G-protein interaction remain poorly understood. Previous studies with GPCRs have identified a highly conserved, negatively charged aspartate at position 2.50 (from TMH 2) to be crucial for ligand binding and/or receptor function (Tao and Abood, 1998; Xu et al., 1999; Wilson and Limbird, 2000) . D2.50 (D163 in CB 1 and D80 in CB 2 ) was demonstrated to be important for G-protein coupling and signal transduction and not ligand binding (Tao and Abood, 1998; Roche et al., 1999; Nie and Lewis, 2001 ). In the µ opioid receptor, D2.50 is also crucial for ligand binding and Gprotein coupling (Xu et al., 1999) . Additionally, D2.50 (in TMH 2) was shown to interact This article has not been copyedited and formatted. The final version may differ from this version. JPET Fast Forward. Published on January 3, 2008 as DOI: 10.1124 at ASPET Journals on July 8, 2017
jpet.aspetjournals.org Downloaded from JPET # 133256 5 with N7.39 (in TMH 7) to modulate receptor function possibly through an ionic interaction (Xu et al., 1999) . Similarly, in the α 2A adrenergic receptor, D2.50 (D79) together with N422 has been shown to be crucial for maintaining the structural integrity of the receptor (Wilson and Limbird, 2000) . Similar charged interactions between residues in the gonadotrophinreleasing hormone receptor and 5HT 2A receptor suggest that TMH 2 and TMH 7 are proximal to each other and residue(s) within these domains are important for receptor activation (Zhou et al., 1994; Sealfon et al., 1995) .
I2.62 (in hCB 1 ) is present at a homologous position in the melanocortin receptor, MC4R, a GPCR. The MC4R is involved in modulating energy homeostatis and regulation of appetite (Fan et al., 2005; Adan et al., 2006) . Mutations or disruption in the signaling of the human MC4R has been shown to result in hyperphagia and severe childhood obesity (Farooqi et al., 2003; Adan et al., 2006) . Mutants of the residue, I2.62 in the MC4R have been implicated for intracellular retention and loss of function of the receptor (LubranoBerthelier et al., 2003; Tao and Segaloff, 2005) . Specifically, the mutated MC4R residue, I102T (I2.62T) resulted in reduced ligand binding and consequently a reduced signaling (Tao and Segaloff, 2005) .
In the present study, we investigated the role of negatively charged residue, D2.63 (D176) in CB 1 receptor function by replacing it with glutamate (D2.63E) or asparagine (D2.63N). D2.63 is unique; whereas it is highly conserved in all species of the CB 1 receptor, an asparagine residue is present at equivalent position in the CB 2 receptor ( Figure 1A ). The residues investigated in this study, I2.62 and D2.63 are located closer to the top of TMH 2 (located upstream to D2.50) towards the extracellular region making them accessible to ligands ( Figure 1B) . Our results suggest that although isoleucine and aspartate residue are This article has not been copyedited and formatted. The final version may differ from this version. Amino Acid Numbering. The numbering scheme suggested by Ballesteros and colleagues was employed here. In this system, the most highly conserved residue in each transmembrane helix (TMH) is assigned a locant of .50. This number is preceded by the TMH number and followed in parentheses by the sequence number. All other residues in a TMH are numbered relative to this residue.
Mutagenesis and Cell Culture. The D2.63N, D2.63E, I2.62T, and I2.62T-D2.63N mutants of the human CB 1 in the vector, pcDNA3 were constructed using the QuikChange sitedirected mutagenesis kit (Stratagene, La Jolla, CA). The mutagenic oligonucleotides used were 27-33 base pairs long. Restriction endonuclease digestion and DNA sequencing subsequently confirmed the presence of the mutation. Stably transfected HEK 293 cell lines were created by transfection with wild-type or mutant CB 1 -pcDNA3 cDNA by the Lipofectamine reagent (Invitrogen, Carlsbad, CA) and selected in growth medium containing geneticin (1 mg/ml) as previously described (McAllister et al., 2003) .
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The GTPγS assay was initiated by the addition of 20 µg of membrane protein into silanized glass tubes containing 0.1 nM [ 35 S]GTPγS, 10 µM GDP in GTPγS binding buffer (50 mM Tris-HCl, 100 mM NaCl, 3 mM MgCl 2 , 0.2 mM EGTA, 0.1% BSA, pH7.4).
Nonspecific binding was assessed in the presence of 20 µM unlabeled GTPγS. Free and bound radioligand were separated and bound radioactivity was quantified as described above.
The specific basal counts (in the absence of an agonist) estimated were an indication of the receptors' constitutive activity. Figure 4 ).
Likewise, the K i value of the inverse agonist AM281 was also altered from 21 nM (on WT hCB 1 ) to 78 nM, 21 nM, and 292 nM on the D2.63N, I2.62T, and I2.62T-D2.63N mutant hCB 1 respectively ( Figure 4B ). investigated. However, a reduction in the agonist-induced maximal stimulation (E max ) was observed at this mutant as compared to WT receptor (data not shown). The lower E max seen for D2.63E mutant can be attributed to reduced levels of receptor expression (Table I) .
Agonist-stimulated GTPγS
In contrast, the charge-neutralization mutation, D2.63N, resulted in an increase of the EC 50 value for WIN55,212-2, CP55,940, AM4056, and HU210 to ~ 37 nM (8-fold), 15 nM (13-fold), 1.2 nM (44-fold), and 0.8 nM (11-fold) respectively, representing a drastic reduction in agonist sensitivity (Table III, Figure 5 ). Thus, while binding affinities were not altered, reductions in agonist potency were significant. Similarly, at the I2.62T mutant, the potency of WIN55,212-2, CP55,940, AM4056, and HU210-induced receptor activation were reduced to 48 nM (9-fold), 3.3 nM (3-fold), 0.2 nM (8-fold), and 0.5 nM (7-fold). 
Discussion
Although neither CB 1 nor CB 2 proteins have been crystallized, much of the structural information on these proteins has been gained from biochemical, mutational, and modeling studies. Despite our accumulating knowledge of receptor structure, the chain of events triggered by binding of ligands to the CB 1 receptor remains poorly characterized. In the present study, we demonstrate that two previously uncharacterized residues, isoleucine and aspartate at position 2.62 and 2.63 respectively, in the second transmembrane domain of the CB 1 receptor are crucial for signal transduction, but do not participate in high affinity agonist binding.
Whereas residues from the TMH 2 of the CB 1 and CB 2 receptor are predominantly conserved, the aspartate residue at position 2.63 in the CB 1 receptor has an asparagine at the equivalent position in the CB 2 receptor. The lack of effect of the CB 2 receptor selective agonist, HU-308 in the mutant hCB 1 receptors suggests that this divergent residue is not responsible for the differential interaction of ligands in CB 1 and CB 2 receptors.
The present study demonstrates that mutation of I2.62 and D2.63 does not cause any major global alteration in structure and/or assembly of the receptor as no detrimental effect on high affinity CB 1 agonist binding and receptor expression were observed. One notable exception was a modest reduction (< 2-fold) in receptor expression (B max ) on the D2.63E mutant. However, the overlapping confidence intervals of the WT and D2.63E B max values suggest that the difference is not significant. In contrast, that the D2.63N mutant had a significantly higher receptor expression than the WT might explain the higher E max observed with this mutant in GTPγS functional assay. The higher E max value observed on the D2.63N
This article has not been copyedited and formatted. The final version may differ from this version. However, mutations in the α 1B -adrenergic receptor that result in constitutively active receptor did not necessarily show a significant attenuation in the affinity of antagonist/inverse agonist (Kjelsberg et al., 1992) . Studies demonstrating unequivocally that inverse agonists have a lower affinity for the active state of the GPCR are lacking (Wade et al., 2001 ). The simplest prediction in our study is that other key features (e.g. structural movement associated with receptors' conformational change and/or G-protein coupling) are altered to produce receptor activation. As discussed in the Results section, we suggest that mutation of these residues has not altered the basal constitutive activity of the receptor, but have a modest effect on the binding of inverse agonist. Additionally, the unaltered potency and efficacy of SR141716A Naturally occurring variants of I102 in the MC4R (homologous to I2.62 in hCB 1 ) result in loss-of-function of the receptor (Tao and Segaloff, 2005) . Furthermore, the MC4R has been implicated to modulate energy metabolism and appetite regulation (Farooqi et al., 2003; Fan et al., 2005; Tao, 2005; Adan et al., 2006) . Stimulation of MC4R activates the adenylyl cyclase pathway and the interference of its signaling pathway has been associated with hyperphagia, hyperglycemia, and obesity (Huszar et al., 1997) . Since the endocannabinoid system is being exploited for its ability to control appetite (Despres, 2007) , extrapolating findings from the MC4R to the CB 1 receptor can serve as a valuable insight to the role of domain(s) in the CB 1 protein that modulate similar effects. Although our results do not point for a direct role of the I2.62 residue in modulating CB 1 receptor function, in combination with D2.63N, a synergistic effect on activity was observed.
Mutation of D2.63 in the CXCR4 chemokine receptor (D97A) resulted in disruption of its chemokine and HIV co-receptor activities (Chabot et al., 1999; Brelot et al., 2000) . The authors postulated an electrostatic interaction may be interrupted in the D2.63A mutation.
Intriguingly, a D2.63(97)N somatic mutation of CXCR4 was found to be associated with medulloblastomas (Schuller et al., 2005) , further supporting a role for this residue in signal transduction. Our present findings with the D2.63N mutant are consistent with previous reports that mutations of a conserved aspartate residue from TMH 2 (D2.50) resulted in reduction in signal transduction without disruption of ligand binding (Tao and Abood, 1998; Roche et al., 1999) . Modeling studies in GPCRs suggest interaction of specific residues located in spatially different domains of the protein via hydrogen bonding to modulate receptor activation (Sealfon et al., 1995 Legends for Figure   Figure 1 : (A) Amino acid sequence alignment of residues from human CB 1 (hCB 1 ), rat CB 1 (rCB 1 ), mouse CB 1 (mCB 1 ), human CB 2 (hCB 2 ) receptor, and rhodopsin (Rho).
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